Pharmaceuticals

Jolly

Jolly released FY2025 Q4 earnings on April 26 Pre-Market (BJT), actual revenue CNY 761.05 M, actual EPS CNY 0.181

Jolly released FY2025 annual earnings on April 26 Pre-Market (BJT), actual revenue CNY 3.041 B (forecast CNY 3.396 B), actual EPS CNY 0.91 (forecast CNY 0.92)

Jolly released FY2026 Q1 earnings on April 26 After-Market (BJT), actual revenue CNY 897.8 M, actual EPS CNY 0.2846

Jolly to Release FY2026 Q1 Earnings on April 27 After-Market (BJT)

Jolly to release FY2025 earnings on April 27, pre-market (BJT), forecast revenue CNY 3.396 B, EPS CNY 0.92

Jolly released FY2025 9 Months Earnings on October 27 During-Market (BJT), Actual Revenue CNY 2.28 B, Actual EPS CNY 0.727

Jolly released FY2025 Q3 earnings on October 27 During-Market (BJT), actual revenue CNY 680.26 M, actual EPS CNY 0.1945

Jolly to Release FY2025 Q3 Earnings on October 28 During-Market (BJT)

ZoLi Pharmaceutical Discloses Equity Ratio in Culligen Pharmaceuticals

Jolly released FY2025 Semi-Annual earnings on August 19 After-Market (BJT), actual revenue CNY 1.599 B, actual EPS CNY 0.5325

Jolly released FY2025 Q2 earnings on August 19 After-Market (BJT), actual revenue CNY 775.03 M, actual EPS CNY 0.2741

Jolly to Release FY2025 Semi-Annual Earnings on August 20, 2025 (BJT)

Zuolie Pharmaceutical and Zhejiang University Collaborate on a Food and Medicine Large Model

Zuolie Pharmaceutical's Q2 2025 Net Profit Expected to Grow

Opening Securities Upgrades Zolu Pharmaceutical to Buy

Zoili Pharmaceutical Completes Animal Pharmacological Study for AD Indication of Modified Uling Capsule

Investor Suggests Zuo Li Pharmaceutical Enhance Marketing of Bailing Capsule

Zuoli Pharmaceutical Secretary Comments on Buyang Capsule Sales and Brand Promotion

Zuoli Pharmaceutical Accepts Multiple Institutional Surveys and Introduces 2024 Performance

Zuoyi Pharmaceutical Q1 2025 Revenue and Net Profit Up 22.52% and 27.2%, Respectively

Ordinary dividend (cash)

Ex Date: 2026.05.28, Cash dividend 0.35 CNY

300181

According to the Zhitong Finance APP, Jolly Pharmaceuticals released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 2.28 billion yuan, a year-on-year increase of 11.48%. The net profit attributable to shareholders of the listed company was 510 million yuan, a year-on-year increase of 21.00%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 509 million yuan, a year-on-year increase of 22.51%. The basic earnings per share were 0.7271 yuan

Zhitong

Jolly Pharmaceuticals released its performance for the first three quarters, with a net profit attributable to the parent company of 510 million yuan, an increase of 21.00%

002026

As global markets face renewed U.S.-China trade tensions, investors are turning to Asian small-cap stocks for opportunities. Shandong Weida Machinery, Zhejiang Jolly Pharmaceutical, and AnHui Jinchun Nonwoven are highlighted for their strong fundamentals and growth potential. Weida Machinery reported a 31.1% earnings growth, Jolly Pharma's net income rose to CNY 373.5 million, and AnHui Jinchun saw a 96.4% earnings increase. These companies demonstrate resilience amid economic uncertainties, making them attractive investment options in the current climate.

Simplywall

SHANDONG WEIDA

Shandong Weida Machinery And 2 Other Asian Small Caps with Promising Potential

Jolly recently stated during a site visit event that the company's digital workshop for solid pharmaceutical preparations is expected to be operational by the end of the year, at which time it will simultaneously meet the demand for capsule, tablet, and other dosage form products

Jolly: The digital workshop for solid pharmaceutical preparations is expected to be operational by the end of the year

Jolly stated in an institutional survey that the research and development work for Lingyi Biotech's Parkinson's pipeline LY-N001 is ongoing, with major preclinical studies completed. This pipeline targets Parkinson's subtype patients associated with GBA1 gene mutations, with plans for IND applications and clinical research in China and the United States in the future. Lingyi Biotech focuses on the research and development of innovative drugs for single-gene genetic diseases and plans to increase its capital by 20 million yuan in April 2025

Jolly: The research and development work on the Parkinson's pipeline LY-N001 of Lingyi Biotech is ongoing

According to the Zhitong Finance APP, Jolly released its semi-annual report for 2025, showing an operating income of 1.599 billion yuan, a year-on-year increase of 11.99%. The net profit attributable to shareholders of the listed company was 374 million yuan, a year-on-year increase of 26.16%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 372 million yuan, a year-on-year increase of 27.24%. The basic earnings per share were 0.5325 yuan

Jolly released its performance for the first half of the year, with a net profit attributable to the parent company of 374 million yuan, an increase of 26.16%

Jolly Pharmaceutical signed an agreement with Zhejiang University to jointly establish the Intelligent Empowerment Food and Drug Joint Research and Development Center, planning to invest 20 million yuan. The center will be managed by the College of Biological System Engineering and Food Science at Zhejiang University, with the College of Computer Science and Technology participating in research and development, focusing on the formulation and process of AI-enabled functional foods using Wu Ling mushrooms

Jolly will jointly establish a Smart Empowerment Food and Drug Research and Development Center with Zhejiang University

Jolly expects its net profit attributable to shareholders in the first half of 2025 to be between 368 million yuan and 388 million yuan, a year-on-year increase of 24.30% to 31.06%. The net profit after deducting non-recurring gains and losses is expected to be between 366 million yuan and 386 million yuan, a year-on-year increase of 25.36% to 32.21%. The company's operating revenue is expected to grow by approximately 12% year-on-year, mainly benefiting from the market expansion of core products such as Wuling capsules, Bailing tablets, and Lingze tablets

Jolly announced a profit forecast, expecting a net profit attributable to the parent company of 368 million to 388 million yuan in the first half of the year, a year-on-year increase of 24.30% to 31.06%

300485

603716

688520

002581

688068

Thalys has gained three consecutive trading limits, while Sinocelltech, Microchip Biotech, Science Sun Pharm, Changchun High-tech, and Sinobioway Medicine have all risen over 5%. Additionally, Huahai Pharmaceutical, Jolly, Hotgen, and others have followed suit. In terms of news, the National Healthcare Security Administration and the National Health Commission recently jointly issued "Several Measures to Support the High-Quality Development of Innovative Drugs," proposing 16 measures in 5 areas, emphasizing full-chain support for the research and development, market access, hospital use, and diversified payment of innovative drugs

Science Sun Pharm

Thalys

Sinocelltech

Sinobioway Medicine

Hotgen

Chipscreen

huahaipharm

CCHT

Innovative drug concept stocks are repeatedly active, Thalys has three consecutive limit-ups

000566

300149

300683

Recently, due to the booming innovative drug market, CAR-T therapy concept stocks have also become more active in trading. According to data from Data Treasure, the average daily trading volume of concept stocks since June has reached 324 million yuan, an increase of 45.95% compared to the previous month. Among the 14 concept stocks, the average daily trading volume has increased by more than 50% since June, with ChemPartner, HITECK, HAINAN HAIYAO, Sinocelltech, and Jolly showing the highest increases

HAINAN HAIYAO

ChemPartner

HITECK

Overview of CAR-T therapy concept stocks with the highest increase in trading volume

In June 2025, U.S. stocks have shown resilience amid trade policy complexities and inflation fluctuations, with growth companies featuring high insider ownership emerging as strong investment options. Notable firms include 3Peak, Qi An Xin Technology Group, and Zhejiang Jolly Pharmaceutical, all demonstrating significant revenue growth forecasts and stable insider ownership. Despite some facing net losses, they are projected to achieve profitability within three years, indicating robust growth potential. The article emphasizes the alignment of interests between management and shareholders as a key advantage in uncertain economic conditions.

Insider-Owned Growth Companies Leading The Global Market In June 2025

Jolly(300181.SZ)